RHUMBLINE ADVISERS

Position in TRVI — Trevi Therapeutics, Inc.

CIK 1115418 BOSTON, MA

Position in TRVI

as of Mar 31, 2026 · filed May 12, 2026 Compact

Position Value

$1,301,097

-$25,046 QoQ

Shares Held

109,061

+3.0% QoQ

Ownership

0.077%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2023

12 quarters on record

Voting authority Sole 21.089115265768697.ToString("F0")% Shared 0.ToString("F0")% None 78.9108847342313.ToString("F0")%

Healthcare · as of Mar 31, 2026

RHUMBLINE ADVISERS holds $1,238,262,141 across 282 Biotechnology names. TRVI ranks #105 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	423,140	$188,948,935
2	REGN	Regeneron Pharmaceuticals, Inc.	157,781	$121,907,911
3	INCY	Incyte Corp	693,665	$65,287,749
4	ALNY	Alnylam Pharmaceuticals, Inc.	195,277	$64,611,300
5	INSM	INSMED Inc	272,615	$44,578,004
6	JAZZ	Jazz Pharmaceuticals plc	164,542	$31,106,665
7	EXEL	Exelixis, Inc.	723,931	$31,049,400
8	ROIV	Roivant Sciences Ltd.	1,113,266	$30,837,468

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,301,097	109,061	+3.0%	Shares	Sole	2026-05-12
2025-12-31	$1,326,143	105,922	-7.9%	Shares	Sole	2026-02-13
2025-09-30	$1,052,451	115,022	+8.1%	Shares	Sole	2025-11-06
2025-06-30	$582,018	106,402	+17.6%	Shares	Sole	2025-08-12
2025-03-31	$569,131	90,482	+13.3%	Shares	Sole	2025-05-29
2024-12-31	$329,080	79,874	-2.6%	Shares	Sole	2025-05-29
2024-09-30	$273,783	81,971	+9.0%	Shares	Sole	2024-11-12
2024-06-30	$224,149	75,218	+44.8%	Shares	Sole	2024-08-01
2024-03-31	$179,244	51,955	+1.0%	Shares	Sole	2024-05-09
2023-12-31	$68,961	51,464	-5.2%	Shares	Sole	2024-02-08
2023-09-30	$118,312	54,272	+8.4%	Shares	Sole	2023-11-09
2023-06-30	$119,636	50,057	—	Shares	Sole	2023-08-08
No filing history on record for this holder in this stock.